drugset / Trial / NCT02609815

Initial Combination of Gemigliptin and Metformin on Microbiota Change

NCT02609815

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate gut microbiota change and glucose lowering effect of initial combination therapy of gemigliptin and metformin compared to glimepiride and metformin in obese patients with type 2 diabetes.

Timeline

Start
2015-11-01
Primary completion
2021-03-15
Completion
2021-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg
Comparator Glimepiride Small molecule 1 mg
Subject Metformin Small molecule 500 mg
Subject Metformin Small molecule 1000 mg